Skip to main content

Table 3 Treatment outcome according to mutation subtype in patients treated with EGFR-TKI

From: Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Mutation subtype

PFS range (months)*

De novo T790 M plus del19 (n = 3)

6.5–11.8

L861Q (n = 4)

1.2–12.6

G719X (n = 3)

0.5–2.8

G719X plus S768I (n = 2)

7.8–22.5

G719X plus E709A (n = 1)

17.6

Del19 plus L858R (n = 2)

13.3–16.4

Del19 plus KRAS (n = 1)

11.9

  1. Abbreviations: PFS progression-free survival
  2. *According to RECIST (response evaluation criteria in solid tumors) criteria
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us